John Cairns

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/689934/publications.pdf

Version: 2024-02-01

54 papers 1,862 citations

331670 21 h-index 289244 40 g-index

56 all docs

56
docs citations

times ranked

56

2885 citing authors

#	Article	IF	CITATIONS
1	Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review. PharmacoEconomics - Open, 2022, 6, 147-167.	1.8	9
2	Can patients improve the quality of care they receive? Experimental evidence from Senegal. World Development, 2022, 150, 105740.	4.9	8
3	Protocol for data extraction: how real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy. BMJ Open, 2022, 12, e055985.	1.9	6
4	The economics of vision impairment and its leading causes: A systematic review. EClinicalMedicine, 2022, 46, 101354.	7.1	24
5	Discrete choice experiments: An overview of experience to date in haemophilia. The Journal of Haemophilia Practice, 2022, 9, 50-63.	0.4	O
6	Payer and Implementation Challenges with Advanced Therapy Medicinal Products (ATMPs). BioDrugs, 2021, 35, 1-5.	4.6	6
7	The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. The Lancet Global Health, 2021, 9, e489-e551.	6.3	549
8	Stated versus revealed preferences: An approach to reduce bias. Health Economics (United Kingdom), 2021, 30, 1095-1123.	1.7	28
9	Global economic productivity losses from vision impairment and blindness. EClinicalMedicine, 2021, 35, 100852.	7.1	71
10	How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review. BMC Cancer, 2021, 21, 980.	2.6	6
11	Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods study. Health Economics, Policy and Law, 2020, 15, 386-402.	1.8	10
12	Cost-Effectiveness Analysis of Screening for Persistent Hepatitis E Virus Infection in Solid Organ Transplant Patients in the United Kingdom: A Model-Based Economic Evaluation. Value in Health, 2020, 23, 309-318.	0.3	7
13	Using Animation to Self-Report Health: A Randomized Experiment with Children. Patient, 2020, 13, 175-188.	2.7	6
14	Recipient Comorbidity and Survival Outcomes After Kidney Transplantation: A UK-wide Prospective Cohort Study. Transplantation, 2020, 104, 1246-1255.	1.0	30
15	Estimating the global cost of vision impairment and its major causes: protocol for a systematic review. BMJ Open, 2020, 10, e036689.	1.9	11
16	HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?. PharmacoEconomics - Open, 2020, 4, 529-539.	1.8	3
17	Survival analysis of colorectal cancer patients in a Thai hospital-based cancer registry. Expert Review of Gastroenterology and Hepatology, 2020, 14, 291-300.	3.0	11
18	Disagreement on cancer drug decisions in Europe. International Journal of Technology Assessment in Health Care, 2020, 36, 232-238.	0.5	3

#	Article	IF	Citations
19	A Mobile Phone–Based Support Intervention to Increase Use of Postabortion Family Planning in Cambodia: Cost-Effectiveness Evaluation. JMIR MHealth and UHealth, 2020, 8, e16276.	3.7	6
20	Measuring patient trust: Comparing measures from a survey and an economic experiment. Health Economics (United Kingdom), 2019, 28, 641-652.	1.7	16
21	What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries. Health Policy, 2019, 123, 130-139.	3.0	22
22	Variation in Practice Patterns for Listing Patients for Renal Transplantation in the United Kingdom. Transplantation, 2018, 102, 961-968.	1.0	17
23	In search of a common currency: A comparison of seven EQ-5D-5L value sets. Health Economics (United) Tj ETQq1	1.9.7843	14 rgBT /0
24	Are children rational decision makers when they are asked to value their own health? A contingent valuation study conducted with children and their parents. Health Economics (United Kingdom), 2018, 27, e55-e68.	1.7	14
25	Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer. PLoS ONE, 2018, 13, e0204496.	2.5	24
26	The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. European Journal of Cancer, 2018, 93, 89-98.	2.8	14
27	Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling. Value in Health, 2017, 20, 799-808.	0.3	15
28	Barriers to living donor kidney transplantation in the United Kingdom: a national observational study. Nephrology Dialysis Transplantation, 2017, 32, 890-900.	0.7	68
29	External Validity of Contingent Valuation: Comparing Hypothetical and Actual Payments. Health Economics (United Kingdom), 2017, 26, 1467-1473.	1.7	10
30	A systematic literature review of health state utility values in head and neck cancer. Health and Quality of Life Outcomes, 2017, 15, 174.	2.4	34
31	Cancer Biomarkers: Ethics, Economics and Society., 2017,,.		10
32	The dog was acting: Designing an animation tool to enable children and young people to express their views about their health state. Animation Practice Process & Production, 2017, 6, 53-70.	0.1	0
33	Access to Transplantation and Transplant Outcome Measures (ATTOM): study protocol of a UK wide, in-depth, prospective cohort analysis. BMJ Open, 2016, 6, e010377.	1.9	28
34	Effectiveness of a structured educational intervention using psychological delivery methods in children and adolescents with poorly controlled type 1 diabetes: a cluster-randomized controlled trial of the CASCADE intervention. BMJ Open Diabetes Research and Care, 2016, 4, e000165.	2.8	22
35	Measuring the burden of preventable diabetic hospitalisations in the Mexican Institute of Social Security (IMSS). BMC Health Services Research, 2016, 16, 333.	2.2	9
36	Systematic review of health state utility values for economic evaluation of colorectal cancer. Health Economics Review, 2016, 6, 36.	2.0	23

#	Article	lF	CITATIONS
37	The economic benefits of reducing the levels of nitrogen dioxide (NO2) near primary schools: The case of London. Journal of Environmental Management, 2016, 181, 615-622.	7.8	28
38	Using Cost-Effectiveness Evidence to Inform Decisions as to which Health Services to Provide. Health Systems and Reform, 2016, 2, 32-38.	1.2	14
39	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. Journal of Hepatology, 2016, 65, 17-25.	3.7	157
40	Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation. European Journal of Health Economics, 2016, 17, 659-668.	2.8	16
41	The financial and health burden of diabetic ambulatory care sensitive hospitalisations in Mexico. Salud Publica De Mexico, 2016, 58, 33-40.	0.4	9
42	Designing a package of sexual and reproductive health and HIV outreach services to meet the heterogeneous preferences of young people in Malawi: results from a discrete choice experiment. Health Economics Review, 2015, 5, 9.	2.0	26
43	Using ambulatory care sensitive hospitalisations to analyse the effectiveness of primary care services in Mexico. Social Science and Medicine, 2015, 144, 59-68.	3.8	13
44	Economic evaluations of follow-up strategies for cancer survivors: a systematic review and quality appraisal of the literature. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 913-929.	1.4	17
45	Young People's Preferences for Family Planning Service Providers in Rural Malawi: A Discrete Choice Experiment. PLoS ONE, 2015, 10, e0143287.	2.5	31
46	Cost-Effectiveness of Early Infant HIV Diagnosis of HIV-Exposed Infants and Immediate Antiretroviral Therapy in HIV-Infected Children under 24 Months in Thailand. PLoS ONE, 2014, 9, e91004.	2.5	15
47	Patient attitudes towards kidney transplant listing: qualitative findings from the ATTOM study. Nephrology Dialysis Transplantation, 2014, 29, 2144-2150.	0.7	38
48	Using decision mapping to inform the development of a stated choice survey to elicit youth preferences for sexual and reproductive health and HIV services in rural Malawi. Social Science and Medicine, 2014, 105, 93-102.	3.8	20
49	Preparatory study for the revaluation of the EQ-5D tariff: methodology report. Health Technology Assessment, 2014, 18, vii-xxvi, 1-191.	2.8	47
50	Structured, intensive education maximising engagement, motivation and long-term change for children and young people with diabetes: a cluster randomised controlled trial with integral process and economic evaluation – the CASCADE study. Health Technology Assessment, 2014, 18, 1-202.	2.8	63
51	The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop. European Journal of Health Economics, 2013, 14, 789-797.	2.8	140
52	Measurement of Risk Perception in the Offshore Oil and Gas Industry. Risk Management, 2008, 10, 205-217.	2.3	3
53	Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. Health Policy, 2006, 76, 134-143.	3.0	46
54	What are nurses worth?. Nursing Standard (Royal College of Nursing (Great Britain): 1987), 2005, 20, 16-17.	0.1	0